The next generation immune checkpoint inhibitors and stimulators market is estimated to be worth USD 12.5 billion in 2030, predicts Roots Analysis
Roots Analysis is pleased to announce the publication of its recent study, titled, “Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030.”
118
views

Therapies targeting novel inhibitory and stimulatory immunecheckpoints have been shown to possess substantial therapeutic potential, bothas monotherapies and in combination with other interventions, across multipledisease interventions

 

Roots Analysis is pleased to announce the publication of its recentstudy, titled, “NextGeneration Immune Checkpoint Inhibitors and StimulatorsMarket, 2020-2030.

 

The report features an extensive study of the currentmarket landscape, offering an informed opinion on the likely adoption of thesetherapies over the next decade. It features an in-depth analysis, highlightingthe capabilities of various stakeholders engaged in this domain. In addition toother elements, the study includes:

§ A detailed assessment of the current market landscape of drugdevelopers engaged in the development of next generation immune checkpointmodulators. 

§ A detailed analysis of more than 590 completed, ongoing andplanned clinical studies of next generation immune checkpoint inhibitors andstimulators.

§ Detailed profiles of developers of next generation immunecheckpoint modulators (shortlisted on the basis of the number ofpipeline products).

§ An in-depth analysis of more than 490 grants that have beenawarded to research institutes engaged in next generation immune checkpointtherapy-related projects.

§ An analysis of the partnerships that have been establishedin this domain, in the recent past.

§ A competitiveness analysis of biological targets, featuringinsightful pictorial summaries and representations.

§ An analysis of the initiatives of big biopharma playersengaged in this domain.

§ A detailed market forecast, featuring analysis of thecurrent and projected future opportunity across key market segments (listedbelow)

  • Target Disease Indication 

§ Breast Cancer

§ Chronic Lymphocytic Leukemia

§ Colorectal Cancer

§ Head and Neck Cancer

§ Lung Cancer

§ Lupus Nephritis

§ Melanoma

§ Multiple Myeloma

§ Primary Sjögren's Syndrome

§ Others 

  • Target Immune Checkpoint

§ B7-H3

§ CD38

§ CD40

§ CD47

§ Others

  • Mechanism of Action

§ Inhibitory

§ Stimulatory

  • Therapeutic Modality

§ Monoclonal Antibody

§ Small Molecule

  • Type of Therapy 

§ Monotherapy 

§ Combination Therapy

  • Route of Administration

§ Intravenous

§ Subcutaneous

§ Others

  • Key Geographical Region 

§ North America

§ Europe

§ Asia-Pacific and the Rest of the World 

 

Keycompanies covered in the report

§ Bristol Myers Squibb

§ GlaxoSmithKline

§ Incyte

§ Novartis

§ Trillium Therapeutics

 

Formore information plea          se click onthe following link:

https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

 

Other Recent Offerings

1.    NeoantigenTargeted Therapies Market, 2019-2030

2.    BispecificAntibody Therapeutics Market (4th Edition), 2019-2030

3.    GlobalStem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com